At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
silodosin +1 moredrug
Likely dose
silodosin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage
In Brief
A Phase 2 clinical trial evaluating silodosin and placebo for Ureteral Calculi and 2 related conditions. Completed, enrolled 239 participants across 27 sites.
Detailed Summary
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUreteral Calculi, Kidney Stones, Urolithiasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedJun 16, 2010
Enrollment StartJun 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.0 years ago
Interventions
silodosindrug
one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
placebodrug
one placebo capsule orally, once daily, with food for up to 4 weeks